Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Expenses: 2018-2024

Historic Operating Expenses for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$18.9 million.

  • Silence Therapeutics' Operating Expenses fell 5.45% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 204.30%. This contributed to the annual value of -$18.9 million for FY2024, which is 69.70% down from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Operating Expenses is -$18.9 million, which was down 69.70% from -$11.1 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Operating Expenses peaked at $69.9 million during FY2021, and registered a low of -$18.9 million during FY2024.
  • Moreover, its 3-year median value for Operating Expenses was -$11.4 million (2022), whereas its average is -$13.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 59.10% in 2021, then crashed by 116.31% in 2022.
  • Over the past 5 years, Silence Therapeutics' Operating Expenses (MRY) stood at $43.9 million in 2020, then skyrocketed by 59.10% to $69.9 million in 2021, then tumbled by 116.31% to -$11.4 million in 2022, then grew by 2.48% to -$11.1 million in 2023, then crashed by 69.70% to -$18.9 million in 2024.
  • Its Operating Expenses stands at -$18.9 million for FY2024, versus -$11.1 million for FY2023 and -$11.4 million for FY2022.